TNFRSF18 and glioblastoma: The combination of retifanlimab (anti-PD1) and INCAGN01876 (GITR agonist) may offer a novel therapeutic strategy for glioblastoma patients, suggesting an improvement in overcoming the high resistance of glioblastoma to conventional therapies (100).